Sun Pharma Acquires Checkpoint Therapeutics for $355 Million
Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma.
Sun Pharma buys Checkpoint and its new cancer drug
Sun Pharma has made its play just three months after Checkpoint won FDA approval for PD-L1 inhibitor Unloxcyt (cosibelimab) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or radiotherapy.
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
Sun Pharma to acquire Checkpoint Therapeutics Inc for up to USD 355 mn
Sun Pharmaceutical Industries on Monday said it will acquire immunotherapy and targeted oncology firm, Inc for up to USD 355 million.   As per the pact inked by the companies, Sun Pharma will pay upfront USD 4.
Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn
Sun Pharmaceutical Industries has entered into a definitive agreement to acquire Checkpoint Therapeutics, Inc., a Nasdaq-listed immunotherapy and targeted oncology company, for an upfront cash payment of $355 million.
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
India's pharma giant Sun Pharma to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment of $355M. The deal involves an upfront cash payment of $4.
Sun Pharmaceuticals To Acquire Checkpoint Therapeutics For $355 Million, Aiming To Better ‘The Lives Of Skin Cancer Patients’
Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun Pharma’s oncology portfolio with FDA-approved UNLOXCYT for advanced cutaneous squamous cell carcinoma (cSCC).
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLOXCYT,
Sun Pharma is betting big on speciality. Will it pay off?
Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...
Fierce Pharma4d
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Sun Pharma to Acquire Checkpoint Therapeutics
(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...